HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Barr exec

This article was originally published in The Tan Sheet

Executive Summary

G. Frederick Wilkinson will join Barr in the new position of President and COO of Duramed Pharmaceuticals effective in March, the firm announces Jan. 10. Wilkinson is not a replacement for Duramed Research President Carole Ben-Maimon, who announced her resignation in December (1"The Tan Sheet" Jan, 2, 2006, p. 9). Nonetheless, Wilkinson will manage all aspects of the firm's proprietary products subsidiary, which encompasses the emergency contraceptive Plan B. Growth of the proprietary products business over the last five years to $400 mil. in sales makes it "appropriate to have a management structure dedicated to these operations," according to Barr Chairman and COO Bruce Downey. Wilkinson previously served as CEO of Columbia Labs...
Advertisement

Related Content

Barr’s Duramed President Ben-Maimon Plans Departure
Barr’s Duramed President Ben-Maimon Plans Departure

Topics

Advertisement
UsernamePublicRestriction

Register

PS099010

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel